



Optimize glycemic management. **Save money.**

Glytec's eGlycemic Management System® (eGMS) is proven to reduce cost of care.

Our FDA-cleared software (**Glucommander™**) delivers personalized, data-driven insulin dosing recommendations, allowing clinicians to safely and effectively control blood glucose levels in their patients.

Turns out, optimizing glycemic management has a positive side effect for hospitals: **reducing the cost of care for patients requiring insulin.**

In a study comparing the use of the Glucommander eGMS for both IV and subcutaneous insulin to usual care at a 610-bed regional medical center, researchers found:

2,434
fewer hypoglycemic events in the first year

×

\$2,934¹
saved **per** hypoglycemic event



\$7,141,356

total annualized savings in the first year

Length of Stay impact:

One third of that total cost savings came just from LOS reduction:

-1.67 days

reduction in length of stay

\$2,579,200

saved as a result of length of stay reduction

Additional research has shown **\$3,654 in savings per CABG patient** using Glucommander.²

(864) 370-3297

glytecsystems.com

info@glytecsystems.com

How can your hospital save money using Glytec's eGMS?



Reduce the incidence of hypo- and hyperglycemia



Improve value-based care performance



Reduce average length of stay



Reduce readmissions



Use fewer point-of-care blood glucose tests



Save doctors and nurses time



Move patients out of the ICU faster



Negotiate reduced liability insurance premiums

Learn how much your hospital could save by investing in eGlycemic Management with Glytec

Contact Us

The eGlycemic Management System® is a modularized solution for glycemic management across the care continuum that includes Glucommander™. Glucommander™ is a prescription-only software medical device for glycemic management intended to evaluate current as well as cumulative patient blood glucose values coupled with patient information including age, weight and height, and, based on the aggregate of these measurement parameters, whether one or many, recommend an IV dosage of insulin, glucose or saline or a subcutaneous basal and bolus insulin dosing recommendation to adjust and maintain the blood glucose level towards a configurable physician- determined target range. Glucommander™ is indicated for use in adult and pediatric (ages 2-17 years) patients. The measurements and calculations generated are intended to be used by qualified and trained medical personnel in evaluating patient conditions in conjunction with clinical history, symptoms, and other diagnostic measurements, as well as the medical professional's clinical judgement. No medical decision should be based solely on the recommended guidance provided by this software program.

Glucommander™ is only available for use in the United States.

This content is only intended for use in the United States.

References

1. Newsom R, Patty C, Camarena E, et al. Safely Converting an Entire Academic Medical Center From Sliding Scale to Basal Bolus Insulin via Implementation of the eGlycemic Management System. *J Diabetes Sci Technol*. 2018;12(1):53-59. doi:10.1177/1932296817747619
2. Cardona S, Pasquel FJ, Fayman M, et al. Hospitalization costs and clinical outcomes in CABG patients treated with intensive insulin therapy. *Journal of Diabetes and Its Complications*. 2017 Apr;31(4):742-747. DOI: 10.1016/j.jdiacomp.2017.01.003.

(864) 370-3297

glytecsystems.com

info@glytecsystems.com